RA Capital β 2025 Investments
9 investments dated 2025 Β· listed companies and verified rows first Β· show all
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)Helmut Jeggle(Co-Founder)Thang Ho(Chief Development Officer)Crystal MacKay(Chief Operating Officer)
Board seatDerek DiRoccoΒ· per SEC Form D
Hyku Biosciences develops covalent medicines to improve patient outcomes by advancing the scientific boundaries of this therapeutic approach.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Kleem Chaudhary, PhD(President & CEO)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)LAURA TADVALKAR(Director)
BiotechWaltham, US
Qimin Quan(Executive Officer)Philippe Mourere(Executive Officer, Director)Joseph Wilkinson(Executive Officer)Scott Sherman(Executive Officer, Director)Elouise P. Manhertz(Executive Officer)
BoardJohn Boyce(Director)
Board seatAnurag KondapalliΒ· per SEC Form D Β· $4M raise Β· filed Mar 2025
BiotechCharlottesville, US
Allen Cunningham(Executive Officer, Director)Nancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)Shaharyar Khan(Executive Officer, Director)Patrick Enright(Director)
BoardFrancesco De Rubertis(Director)
Board seatDerek DiRoccoΒ· per SEC Form D Β· $57M raise Β· filed Jan 2025
BiotechWaltham, US
CATHERINE RIESEN(Executive Officer)CONY D'CRUZ(Executive Officer, Director, Promoter)CRAIG RANDALL(Executive Officer)
BoardDIAMANTIS XYLAS(Director)DYLAN MORRIS(Director)
Board seatAndrew LevinΒ· per SEC Form D Β· $5M raise Β· filed Aug 2025
BiotechCambridge, US
Livio Valenti(Executive Officer)Kathryn Kosuda(Executive Officer, Director)Matthew Dirckx(Executive Officer)Lynda Tussey(Executive Officer)John Spiridigliozzi(Executive Officer)Weiner Tilsner(Executive Officer)
Board seatPeter KolchinskyΒ· per SEC Form D Β· $10M raise Β· filed Feb 2025
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Quehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)Matthew Fust(Director)Nancy Stagliano, Ph.D.(Director)
BiotechBoulder, US
Theodore Randolph(Director)Romulo Colindres(Executive Officer, Director, Promoter)
BoardGlenn Rockman(Director)Rene Lorenz(Director)Louise Brady(Director)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.